Review Article
Clostridioides difficile Infection in Patients with Chronic Kidney Disease: A Systematic Review
| Outcome | Study | Participants | Results | Baseline | Posttesting | % change |
| Cure rate (no. of patients) | Mullane et al. 2013 [32] | Fidaxomycin stage 3 CKD | 112 | 89 | 79.5 | | | Fidaxomycin stage 4 CKD | 46 | 34 | 73.9 | | | Vancomycin stage 3 CKD | 113 | 91 | 80.5 | | | Vancomycin stage 4 CKD | 50 | 38 | 76.0 | | Cammarota et al. 2015 [33] | FMT | 20 | 18 | 90.0 | | | Vancomycin | 19 | 12 | 63.2 | | Lackowicz et al. 2014 [30] | Nephrology ward patients | 9 | 4 | 44.4 | | Kujawa et al. 2015 [29] | LP299v | 21 | 19 | 90.4 | | | | | | | Recurrence (no. of patients) | Mullane et al. 2013 [32] | Fidaxomycin stage 3 CKD | 89 | 19 | 21.4 | | | Fidaxomycin stage 4 CKD | 34 | 5 | 14.7 | | | Vancomycin stage 3 CKD | 91 | 30 | 33.0 | | | Vancomycin stage 4 CKD | 38 | 12 | 31.6 | | Lackowicz et al. 2014 [30] | Nephrology ward patients | 4 | 3 | 75.0 | | Cammarota et al. 2015 [33] | FMT | 18 | 2 | 11.1 | | | Vancomycin | 17 | 12 | 70.5 | | Kujawa et al. 2015 [29] | LP299v | 21 | 2 | 9.0 | | | | | | | Mortality (no. of patients) | Mullane et al. 2013 [32] | Stage 3 CKD | — | — | — | | | Stage 4 CKD | — | — | — | | Lackowicz et al. 2014 [30] | Nephrology ward patients | 9 | 2 | 22 | | Cammarota et al. 2015 [33] | FMT | 20 | 2 | 10 | | | Vancomycin | 19 | 6 | 31.5 | | | | | | | Duration of diarrhea (days) | Kujawa et al. 2015 [29] | LP299v in the patients with recurrence () | 28 | 9.5 | 33.9 | Number of stools per day | Kujawa et al. 2015 [29] | LP299v in the patients with recurrence () | 8 | 7 | — | Average CRP serum concentration (mg/l) | Kujawa et al. 2015 [29] | LP299v in the patients with recurrence () | 96.5 | 43.8 | |
|
|